Gene Therapy, A Targeted Treatment for Diabetic Nephropathy

被引:9
作者
Lin, X. [1 ,2 ,3 ]
Tao, L. [3 ]
Tang, D. [1 ,2 ]
机构
[1] McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON L8S 4L8, Canada
[2] St Josephs Hosp, Hamilton Ctr Kidney Res, Hamilton, ON L8N 4A6, Canada
[3] Cent S Univ, Xiangya Hosp, Div Nephrol, Dept Med, Changsha, Hunan, Peoples R China
关键词
Diabetes; diabetic nephropathy; gene therapy; ANGIOTENSIN-CONVERTING ENZYME; TISSUE GROWTH-FACTOR; TGF-BETA ANTIBODY; RENAL-DISEASE; MOUSE MODEL; EXPERIMENTAL GLOMERULONEPHRITIS; SOLUBLE BETAGLYCAN; GLOMERULAR INJURY; PODOCYTE NUMBER; MESANGIAL CELLS;
D O I
10.2174/09298673113209990183
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diabetic nephropathy (DN) is a major complication of diabetes and the leading cause of end-stage renal disease (ESRD). Approximately, one third of diabetic patients develop diabetic nephropathy. As diabetes and its associated metabolic diseases are becoming epidemic, DN is emerging as a major health threat to humans. Currently, there are no effective therapeutic treatments for the disease. As a result, most DN cases progress to ESRD; patients with ESRD will need to undergo renal replacement through either dialysis or kidney transplantation. Therefore, developing new and effective means to control DN has been a major focus in the diabetes research. DN is a complex disease with pathological changes occurred in the glomerulus and renal tubules. It is, nonetheless, widely believed that the primary defects lie in the glomeruli, which lead to disrupting the integrity of the glomerular filtration barrier. While a variety of factors contribute to the impairment of glomerular filtration function, a large body of evidence demonstrates that damage in podocytes is the leading cause. Renal fibrosis plays critical roles in promoting DN progression. The primary mechanism responsible for renal fibrosis is abnormal activation of the transforming growth factor (TGF)-pathway. Based on this understanding of DN pathogenesis, one strategy to control DN is to specifically protect podocytes from diabetes-induced injuries and to inhibit TGF-signaling using gene therapy methodology. In this review, we will discuss the current research effort in developing gene therapy for DN.
引用
收藏
页码:3774 / 3784
页数:11
相关论文
共 109 条
[41]   APPLICATION OF AN ADENOVIRAL VECTOR ENCODING SOLUBLE TRANSFORMING GROWTH FACTOR-β TYPE II RECEPTOR TO THE TREATMENT OF DIABETIC NEPHROPATHY IN MICE [J].
Kondo, Takehito ;
Takemura, Genzou ;
Kosai, Ken-ichiro ;
Ohno, Takamasa ;
Takahashi, Tomoyuki ;
Esaki, Masayasu ;
Goto, Kazuko ;
Maruyama, Rumi ;
Murata, Ichijiro ;
Minatoguchi, Shinya ;
Fujiwara, Takako ;
Fujiwara, Hisayoshi .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2008, 35 (11) :1288-1293
[42]   Expression of podocyte-associated molecules in acquired human kidney diseases [J].
Koop, K ;
Eikmans, M ;
Baelde, HJ ;
Kawachi, H ;
De Heer, E ;
Paul, LC ;
Bruijn, JA .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (08) :2063-2071
[43]   Delivery of plasmid DNA expressing small interference RNA for TGF-β type II receptor by cationized gelatin to prevent interstitial renal fibrosis [J].
Kushibiki, T ;
Nagata-Nakajima, N ;
Sugai, M ;
Shimizu, A ;
Tabata, Y .
JOURNAL OF CONTROLLED RELEASE, 2005, 105 (03) :318-331
[44]   Pathogenesis of nonimmune glomerulopathies [J].
Kwoh, Christopher ;
Shannon, M. Brendan ;
Miner, Jeffrey H. ;
Shaw, Andrey .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2006, 1 (01) :349-374
[45]   The prevention of diabetic microvascular complications of diabetes: Is there a role for lipid lowering? [J].
Leiter, LA .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 68 :S3-S14
[46]   Treatment of diabetic nephropathy with angiotensin II receptor antagonist [J].
E. J. Lewis ;
J. B. Lewis .
Clinical and Experimental Nephrology, 2003, 7 (1) :1-8
[47]   Angiotensin-Converting Enzyme (ACE) 2 Overexpression Ameliorates Glomerular Injury in a Rat Model of Diabetic Nephropathy: A Comparison with ACE Inhibition [J].
Liu, Chun Xi ;
Hu, Qin ;
Wang, Yan ;
Zhang, Wei ;
Ma, Zhi Yong ;
Feng, Jin Bo ;
Wang, Rong ;
Wang, Xu Ping ;
Dong, Bo ;
Gao, Fei ;
Zhang, Ming Xiang ;
Zhang, Yun .
MOLECULAR MEDICINE, 2011, 17 (1-2) :59-69
[48]   BETAGLYCAN PRESENTS LIGAND TO THE TGF-BETA SIGNALING RECEPTOR [J].
LOPEZCASILLAS, F ;
WRANA, JL ;
MASSAGUE, J .
CELL, 1993, 73 (07) :1435-1444
[49]   The podocyte as a target for therapies-new and old [J].
Mathieson, Peter W. .
NATURE REVIEWS NEPHROLOGY, 2012, 8 (01) :52-56
[50]   Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy [J].
McGowan T.A. ;
Zhu Y. ;
Sharma K. .
Current Diabetes Reports, 2004, 4 (6) :447-454